Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Viatris Inc (VTRS) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance

Viatris IncTrade
Vanguard International High Dividend Yield ETFTrade

Price performance (Past 24H)

Key statistics

Viatris Inc vs Vanguard International High Dividend Yield ETF — how do they compare? Viatris Inc trades at $17.64 (market cap $20.03B), while Vanguard International High Dividend Yield ETF trades at $100.44 (market cap $22.80B). The key difference: Viatris Inc and Vanguard International High Dividend Yield ETF are close in size by market cap, and Viatris Inc pays a 2.75% dividend while Vanguard International High Dividend Yield ETF pays none. Which is the better fit depends on your goals.

VTRSVYMI
Market Cap
$20.03B$22.80B
Volume
14,109,977748,441
Sector
HealthBroad Market / Factor
52-Week High
$18.27$107.13
52-Week Low
$9.74$82.92
Typical Hold Time
57 Days—
Enterprise Value
$32.15B—
Dividend Yield
2.75%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Viatris Inc

Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.

The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.

Vanguard International High Dividend Yield ETF

VYMI trades at $100.27 with minimal daily movement (+0.04%). Technical indicators show a bearish trend with moving averages signaling caution, though oscillators are neutral. Recent news highlights institutional accumulation and positive performance comparisons to peers. The ETF's international high-dividend strategy focuses on financials, energy, and healthcare sectors.

Outlook remains mixed: bullish sentiment from media and institutional inflows contrasts with bearish technicals. Key opportunities include sector alignment with rising rates and attractive yield; risks involve global economic volatility and concentrated financial exposure. Investors should weigh dividend stability against technical weakness.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

VTRS
100% Buy0% Sell
Avg holding period · 57 Days
VYMI
65% Buy35% Sell

Top news

Latest headlines on both assets

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →

About Vanguard International High Dividend Yield ETF

VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.

Read more on VYMI →